HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).

GutSep 7, 2026 (epub)
Clinical ResearchGastroenterologyInfectious Diseases

Edo J Dongelmans, Lesley A Patmore, Seng Gee Lim et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the impact of peg-interferon (peg-IFN) therapy added to nucleos(t)ide analogue (NA) treatment in chronic hepatitis B patients. Among 581 participants, 8.6% achieved HBsAg loss at the end of follow-up, with significant declines in HBsAg levels observed. The study highlights the potential of peg-IFN to enhance treatment outcomes in this population.

Key findings

  • 8.6% of patients achieved HBsAg loss at end of follow-up.
  • In patients with SOT HBsAg ≥1000 IU/mL, 29.7% achieved HBsAg <1000 at 24 weeks.
  • At 48 weeks, 47.5% of patients with SOT HBsAg ≥1000 IU/mL reached HBsAg <1000.

Why it matters

Understanding the efficacy of peg-IFN in combination with NA therapy is crucial for optimizing treatment strategies in chronic hepatitis B, potentially leading to improved patient outcomes and enhanced chances of achieving a functional cure.

Source

PubMed · PMID 41198171

Published in Gut. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.